The Power of Integration: MedTech Impact Partners & Boulder Clinical Science
FOR IMMEDIATE RELEASE
MedTech Impact Partners and Boulder Clinical Science Partner to Streamline Drug & Device Development
Encino, CA – June 3, 2025 – MedTech Impact Partners (MIP), a leading regulatory strategy consulting firm, and Boulder Clinical Science (BCS), a specialized Clinical Research Organization (CRO) focused on early-stage companies, today announced a strategic partnership designed to significantly de-risk drug and device development for their clients.
By formally integrating their services, MIP and BCS will offer a seamless and comprehensive approach to navigating the complexities of the MedTech landscape. This collaboration combines MIP’s timely expert regulatory insights and tailored solutions with BCS’s proficiency in capital-efficient clinical trial protocol design and execution.
“We are pleased to formalize our long-standing collaborative relationship with Boulder Clinical Science,” said Kwame Ulmer at MedTech Impact Partners. “Our clients increasingly seek integrated solutions that address both the regulatory and clinical pathways. This partnership allows us to provide a more interconnected and efficient approach, accelerating their path to market while managing risks and increasing value.”
Boulder Clinical Science echoed this sentiment. “ Kimberly Martin at Boulder Clinical Science stated, “MedTech Impact Partners’ exceptional regulatory acumen perfectly complements our clinical trial capabilities. Together, we can offer start-ups and established companies alike a powerful combination of strategic guidance and operational excellence, all while maintaining cost-effectiveness.”
Both MedTech Impact Partners and Boulder Clinical Science have established reputations for supporting an impressive client portfolio since 2020. This partnership formalizes their commitment to providing clients with:
De-risked Development: Integrated regulatory and clinical strategies from the outset to anticipate and address potential challenges.
Accelerated Market Launch: Streamlined processes and expert guidance to expedite the journey from concept to commercialization.
Enhanced Efficiency: Leveraging a virtual CRO model from BCS and targeted regulatory solutions from MIP to optimize timelines and budgets.
Comprehensive Support: From initial regulatory strategy and clinical trial design to execution and market access.
This strategic alliance underscores both companies’ dedication to empowering MedTech companies with the expertise and support needed to bring life-changing therapies and technologies to patients.
About MedTech Impact Partners:
MedTech Impact Partners is a regulatory strategy consulting firm leveraging deep regulatory expertise grounded in research and executive-level FDA and MedTech operational experience. MIP delivers timely expert insights and tailored regulatory solutions for MedTech companies, law firms, and investors, focusing on company value creation, accelerating market access, and managing risk.
About Boulder Clinical Science:
Boulder Clinical Science is a CRO specializing in helping start-ups with clinical trial protocol design and execution through all phases of the drug/device development cycle. BCS combines academic and industry expertise with PhD-trained Clinical Scientists and Biostatisticians, utilizing a capital-efficient virtual model to deliver high-quality services at competitive costs.
Contact:
Amelia Dortch
Marketing Partner, MedTech Impact Partners
amelia.dortch@medtechimpactpartners.com
Kimberly Martin, PhD
President and Principal, Boulder Clinical Science